Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 16:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479),...
October 09, 2025 10:23 ET | Source: Fifty 1 Labs, Inc.

Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY) and a cutting-edge innovator at the intersection of AI,...
October 09, 2025 06:01 ET | Source: Research and Markets

1 Day Virtual Digital Technology and Personalisation in Patient Support Programmes Course: Leverage Digital Innovation to Enhance Clinical Studies and Optimize Commercial Drug Delivery (Nov 5, 2025)

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Digital Technology and Personalisation in Patient Support Programmes Training Course (Nov 5, 2025)" training has been added to ...
October 09, 2025 05:45 ET | Source: Research and Markets

Smart Packaging and Electronic Patient Information Training Course: Gain Strategic Insight into e-PIL and SMART Initiatives (ONLINE EVENT: Nov 3rd - Nov 4th, 2025)

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Smart Packaging and Electronic Patient Information Training Course (Nov 3rd - Nov 4th, 2025)" training has been added to ResearchAndMarkets.com's...
October 08, 2025 14:31 ET | Source: Regeneron Pharmaceuticals, Inc.

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval:...
October 08, 2025 13:00 ET | Source: DelveInsight Business Research LLP

CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

New York, USA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight The...
October 08, 2025 08:51 ET | Source: SNS Insider pvt ltd

Global Antibody Drug Conjugates (ADC) Market to Reach USD 29.10 Billion by 2032, Growing at a CAGR of 12.29% | S&S Insider

Austin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Antibody Drug Conjugates Market Size & Growth Analysis: The Antibody Drug Conjugates Market size was valued at USD 12.29 billion in 2024 and is...
October 08, 2025 08:00 ET | Source: Precedence Research

Digital Healthcare Education Market Size Projects to Soar USD 120.67 Billion in 2034

Ottawa, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The global digital healthcare education market size was valued at USD 53.67 billion in 2024 and is predicted to hit around USD 120.67 billion by 2034,...
October 08, 2025 05:12 ET | Source: Research and Markets

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has...
October 08, 2025 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors ...